Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
European Journal of Nuclear Medicine and Molecular Imaging
Published in: European Journal of Nuclear Medicine and Molecular Imaging 5/2010

01-05-2010 | Editorial Commentary

Alpha particles more promising than toxins?

Authors: Jacques Barbet, Michel Chérel, Jean-François Chatal

Published in: European Journal of Nuclear Medicine and Molecular Imaging | Issue 5/2010

Login to get access

Excerpt

The first treatment ever of cancer by radioimmunotherapy (RIT) was performed by William H. Beierwaltes in 1951 and was a success [1]. However, experimentation on this approach really started in 1981 with polyclonal antibodies [2] and radiolabelled monoclonal antibodies were proposed for this purpose by several groups in 1987 and 1988. Research on radioimmunotherapy became more and more active over the years and finally, in 2002 and 2003, radiolabelled monoclonal antibodies, both targeting the CD20 antigen, were approved for marketing for the treatment of follicular non-Hodgkin’s lymphoma. …
Literature
1.
Srivastava SC. Investigators review potential of antibodies in cancer detection and therapy. J Nucl Med 1987;28:143–7.PubMed
2.
Goldenberg DM, Gaffar SA, Bennett SJ, Beach JL. Experimental radioimmunotherapy of a xenografted human colonic tumor (GW-39) producing carcinoembryonic antigen. Cancer Res 1981;41(11 Pt 1):4354–60.PubMed
3.
Blythman HE, Casellas P, Gros O, Gros P, Jansen FK, Paolucci F, et al. Immunotoxins: hybrid molecules of monoclonal antibodies and a toxin subunit specifically kill tumour cells. Nature 1981;290(5802):145–6.CrossRefPubMed
4.
5.
Stasi R. Gemtuzumab ozogamicin: an anti-CD33 immunoconjugate for the treatment of acute myeloid leukaemia. Expert Opin Biol Ther 2008;8(4):527–40.CrossRefPubMed
6.
Liersch T, Meller J, Kulle B, Behr TM, Markus P, Langer C, et al. Phase II trial of carcinoembryonic antigen radioimmunotherapy with 131I-labetuzumab after salvage resection of colorectal metastases in the liver: five-year safety and efficacy results. J Clin Oncol 2005;23(27):6763–70.CrossRefPubMed
7.
Chatal JF, Campion L, Kraeber-Bodéré F, Bardet S, Vuillez JP, Charbonnel B, et al. Survival improvement in patients with medullary thyroid carcinoma who undergo pretargeted anti-carcinoembryonic-antigen radioimmunotherapy: a collaborative study with the French Endocrine Tumor Group. J Clin Oncol 2006;24(11):1705–11.CrossRefPubMed
8.
Kozak RW, Atcher RW, Gansow OA, Friedman AM, Hines JJ, Waldmann TA. Bismuth-212-labeled anti-Tac monoclonal antibody: alpha-particle-emitting radionuclides as modalities for radioimmunotherapy. Proc Natl Acad Sci U S A 1986;83(2):474–8.CrossRefPubMed
9.
Zalutsky MR, Bigner DD. Radioimmunotherapy with alpha-particle emitting radioimmunoconjugates. Acta Oncol 1996;35(3):373–9.CrossRefPubMed
10.
Lewis Phillips GD, Li G, Dugger DL, Crocker LM, Parsons KL, Mai E, et al. Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate. Cancer Res 2008;68(22):9280–90.CrossRefPubMed
11.
Ikeda H, Hideshima T, Fulciniti M, Lutz RJ, Yasui H, Okawa Y, et al. The monoclonal antibody nBT062 conjugated to cytotoxic Maytansinoids has selective cytotoxicity against CD138-positive multiple myeloma cells in vitro and in vivo. Clin Cancer Res 2009;15(12):4028–37.CrossRefPubMed
Metadata
Title
Alpha particles more promising than toxins?
Authors
Jacques Barbet
Michel Chérel
Jean-François Chatal
Publication date
01-05-2010
Publisher
Springer-Verlag
Published in
European Journal of Nuclear Medicine and Molecular Imaging / Issue 5/2010
Print ISSN: 1619-7070
Electronic ISSN: 1619-7089
DOI
https://doi.org/10.1007/s00259-010-1421-5

Other articles of this Issue 5/2010

European Journal of Nuclear Medicine and Molecular Imaging 5/2010 Go to the issue

Original Article

Kinetic analysis of the cannabinoid-1 receptor PET tracer [18F]MK-9470 in human brain

Editorial Commentary

Hybrid versus fusion imaging: are we moving forward judiciously?

Original Article

A theoretical dose-escalation study based on biological effective dose in radioimmunotherapy with 90Y-ibritumomab tiuxetan (Zevalin)

Book Review

Torsten B. Moeller and Emil Reif (eds). 2009. Pocket atlas of radiographic positioning

Original Article

Clearance of the high intestinal 18F-FDG uptake associated with metformin after stopping the drug

Original Article

Dose-response assessment of tariquidar and elacridar and regional quantification of P-glycoprotein inhibition at the rat blood-brain barrier using (R)-[11C]verapamil PET